{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:39:28Z","timestamp":1762868368222},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Hepatitis C virus (HCV) infection is very common in maintenance hemodialysis patients, causing high morbidity and mortality. This study aimed to evaluate the effectiveness and adverse events of direct-acting antivirals (DAAs) in maintenance hemodialysis patients complicated with chronic hepatitis C in real-world clinical practice.<\/jats:p>\n            <jats:p>In this retrospective observational study, hemodialysis patients with chronic hepatitis C infection in the Third Central Hospital of Tianjin outpatient were screened, and appropriate treatment plans were selected accordingly. Totally 25 patients diagnosed with chronic hepatitis C and treated with DAAs for 12 weeks or 24 weeks were included. The sustained virologic response (SVR) rate obtained 12 weeks post-treatment (SVR12) was evaluated. Laboratory indexes and adverse reactions during the treatment process were also assessed.<\/jats:p>\n            <jats:p>A total of 25 cases met the eligibility criteria and provided informed consent. Except for 1 patient who discontinued the treatment due to gastrointestinal bleeding, the remaining 24 cases completed the treatment cycle with 100% rapid virologic response (RVR) and 100% SVR12, with no serious adverse reactions recorded.<\/jats:p>\n            <jats:p>Maintenance hemodialysis patients complicated with chronic hepatitis C in Chinese real-world setting tolerate DAAs very well, with a viral response rate reaching 100%.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000023384","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T17:37:19Z","timestamp":1606153039000},"page":"e23384","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C"],"prefix":"10.1097","volume":"99","author":[{"given":"Chunhong","family":"Li","sequence":"first","affiliation":[{"name":"Depatrment of Nephrology, The Third Central Clinical College of Tianjin Medical University"},{"name":"Department of Nephrology, The Third Central Hospital of Tianjin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liang","sequence":"additional","affiliation":[{"name":"Depatrment of Nephrology, The Third Central Clinical College of Tianjin Medical University"},{"name":"Department of Nephrology, The Third Central Hospital of Tianjin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiling","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Third Central Hospital of Tianjin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Blood Purification Center, The Second Hospital of Tianjin Medical University, Tianjin, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Third Central Hospital of Tianjin"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"R1-20240523","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","article-title":"Hepatitis C virus infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20240523","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.19082\/5646","article-title":"Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection","volume":"9","author":"Moosavy","year":"2017","journal-title":"Electron Physician"},{"key":"R3-20240523","doi-asserted-by":"crossref","first-page":"17265","DOI":"10.3748\/wjg.v20.i46.17265","article-title":"Health care-associated hepatitis C virus infection","volume":"20","author":"Pozzetto","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R4-20240523","first-page":"280","article-title":"Hepatitis C virus treatment in patients with chronic kidney disease and in kidney transplant recipients","volume":"14","author":"Corson","year":"2018","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R5-20240523","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1523-1755.2004.00649.x","article-title":"Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS","volume":"65","author":"Fissell","year":"2004","journal-title":"Kidney Int"},{"key":"R6-20240523","first-page":"857","article-title":"Investigation on the status of blood transmissible diseases in hemodialysis patients in Tianjin","volume":"11","author":"Wang","year":"2016","journal-title":"Chin J Nephrol"},{"key":"R7-20240523","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1093\/ndt\/gfu321","article-title":"Reducing the risk of infection in end-stage kidney failure patients treated by dialysis","volume":"29","author":"Collier","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"R8-20240523","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/IJGM.S127689","article-title":"Hepatitis C treatment: where are we now?","volume":"10","author":"Burstow","year":"2017","journal-title":"Int J Gen Med"},{"key":"R9-20240523","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3390\/medicina54050080","article-title":"Current status of direct acting antiviral agents against hepatitis C virus infection in Pakistan","volume":"54","author":"Khaliq","year":"2018","journal-title":"Medicina (Kaunas)"},{"key":"R10-20240523","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00228-018-2456-y","article-title":"Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden","volume":"74","author":"Frisk","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"R11-20240523","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00535-016-1174-4","article-title":"Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis","volume":"51","author":"Toyoda","year":"2016","journal-title":"J Gastroenterol"},{"key":"R12-20240523","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12882-020-1687-1","article-title":"Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease","volume":"21","author":"Iliescu","year":"2020","journal-title":"BMC Nephrol"},{"key":"R13-20240523","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/COH.0000000000000370","article-title":"Diagnosis of viral hepatitis","volume":"12","author":"Easterbrook","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"R14-20240523","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1478-3231.2011.02660.x","article-title":"Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C","volume":"32","author":"Cardoso","year":"2012","journal-title":"Liver Int"},{"key":"R15-20240523","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/hep.26578","article-title":"AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations","volume":"58","author":"Koh","year":"2013","journal-title":"Hepatology"},{"key":"R16-20240523","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10157-007-0005-6","article-title":"Patterns in the prevalence of hepatitis C virus infection at the start of hemodialysis in Japan","volume":"12","author":"Iwasa","year":"2008","journal-title":"Clin Exp Nephrol"},{"key":"R17-20240523","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.ajkd.2004.12.014","article-title":"Hepatitis C infection is acquired pre-ESRD","volume":"45","author":"Bergman","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R18-20240523","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2893.2012.01633.x","article-title":"Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality","volume":"19","author":"Fabrizi","year":"2012","journal-title":"J Viral Hepat"},{"key":"R19-20240523","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"R20-20240523","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/sdi.12768","article-title":"Summary of the 2018 Kidney Disease Improving Global Outcomes (KDIGO) Guideline on hepatitis C in chronic kidney disease","volume":"32","author":"Gordon","year":"2019","journal-title":"Semin Dial"},{"key":"R21-20240523","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000485710","article-title":"Treatment of hepatitis C virus infection in dialysis patients","volume":"196","author":"Kikuchi","year":"2018","journal-title":"Contrib Nephrol"},{"key":"R22-20240523","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1053\/j.ajkd.2019.12.016","article-title":"KDOQI US Commentary on the 2018 KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C","volume":"75","author":"Roth","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"R23-20240523","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/jgh.12398","article-title":"Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection","volume":"29","author":"Rao","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"R24-20240523","first-page":"1","article-title":"Guidelines for the prevention and treatment of hepatitis C (2015 Version)","volume":"29","year":"2016","journal-title":"Infect Dis Inform"},{"key":"R25-20240523","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2016.04.003","article-title":"Finally, safe and effective treatment options for hepatitis C in hemodialysis patients","volume":"65","author":"Bhamidimarri","year":"2016","journal-title":"J Hepatol"},{"key":"R26-20240523","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jvh.12553","article-title":"Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study","volume":"23","author":"Kawakami","year":"2016","journal-title":"J Viral Hepat"},{"key":"R27-20240523","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00535-019-01556-y","article-title":"Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection","volume":"54","author":"Suda","year":"2019","journal-title":"J Gastroenterol"},{"key":"R28-20240523","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.4254\/wjh.v8.i32.1343","article-title":"Anti-hepatitis C virus drugs and kidney","volume":"8","author":"Carrier","year":"2016","journal-title":"World J Hepatol"},{"key":"R29-20240523","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"R30-20240523","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"R31-20240523","first-page":"962","article-title":"Guidelines for the Prevention and Treatment of Hepatitis C (2015 Version)","volume":"27","year":"2019","journal-title":"Chin J Hepatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T14:18:39Z","timestamp":1716473919000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":31,"journal-issue":{"issue":"48","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023384","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,25]]}}}